OCTOBER 2026 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
AIFA October 1 Camizestrant – BC ESR1. The Italian Medicines Agency (AIFA) has authorised the marketing of the selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative […]